Crestline Management’s United Therapeutics UTHR Stock Holding History

Crestline Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,306	Closed	-$3.42M	–	202
2022 Q4	$3.42M	Buy	12,306 +125	+1%	+$31.6K	0.5%	61
2022 Q3	$2.55M	Buy	12,181 +5,123	+73%	+$1.15M	0.34%	71
2022 Q2	$1.66M	Sell	7,058 -1,601	-18%	-$325K	0.22%	95
2022 Q1	$1.55M	Sell	8,659 -11,597	-57%	-$2.21M	0.19%	107
2021 Q4	$4.38M	Buy	20,256 +3,014	+17%	+$592K	0.33%	59
2021 Q3	$3.18M	Buy	17,242 +5,987	+53%	+$1.18M	0.3%	74
2021 Q2	$2.02M	Buy	+11,255	New	+$2.14M	0.17%	81
2019 Q4	–	Sell	-37,500	Closed	-$2.99M	–	91
2019 Q3	$2.99M	Buy	37,500 +24,500	+188%	+$1.97M	0.48%	37
2019 Q2	$1.01M	Buy	+13,000	New	+$1.22M	0.14%	59

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Crestline Management's UTHR Position: Q1 2023 in Review

Crestline Management sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 12,306 shares — an estimated $3.42M sold.

Crestline Management first reported a position in UTHR in Q2 2019 and held it in 9 quarters. The position peaked at $4.38M in Q4 2021. 505 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

Crestline Management reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
Crestline Management sold 12,306 United Therapeutics shares in Q1 2023, an estimated $3.42M.
Crestline Management first reported a position in United Therapeutics in Q2 2019 and held it in 9 quarters.
Crestline Management's United Therapeutics position peaked at $4.38M in Q4 2021.
505 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Crestline Management's 13F filing for Q1 2023, filed 15 May 2023.